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Biobanks in the era of personalized




Biobanks are an important compound of personalized medicine and strongly support the scientific progress in
stratification of population and biomarker discovery and validation due to progress in personalized medicine.
Biobanks are an essential tool for new drug discoveries and drug development. Biobanks play an important
role in the whole process of patient prevention and prediction, follow-up, and therapy monitoring and
optimalization. Biobanks have the specificity in that they cover multidisciplinary approach to the human
health combining biological and medical approaches, as well as informative bioinformatics technologies,
computationing, and modeling. The importance of biobanks has during the last decade increased in variety
and capacity from small collections of samples to large-scale national or international repositories. Collected
samples are population-based, disease-specific or rare diseases originating from a diverse profile of individuals.
There are various purposes of biobanks, such as diagnostics, pharmacology, or research. Biobanks involve,
store, and operate with specific personal information, and as a consequence, such a diversity of biobanking is
associated with a broad spectrum of ethical and legal issues. Biobanks are an international phenomenon
because any single country, state, or society at the moment is not able to cover all issues involving the
whole biobank problematic. Biobanks have an enormous innovative potential in the whole process of
biomedical research in the twenty-first century.
Keywords: Biobanks, Types, History, Definitions, Role of biobanks, Ethical and legal issues, Predictive
preventive personalized medicine
Background
A new era of medical research brought in the last decade
a lot of new discoveries, new knowledge, and informa-
tion and is, by many authors, called the era of personal-
ized medicine. The term covers not only new knowledge
and approaches but also new paradigms of current
medicine from curing to prevention. It also means a
combination of new multidisciplinary approaches to bet-
ter understand health and diseases. A new era of medical
research brings new questions that have to be answered.
Personalized medicine is as a new approach to the pa-
tient built on several pillars: -omics methods (proteomics,
metabolomics, and epigenomics), systems medicine, bio-
informatics, and biobanks, and the implementation of
personalized medicine requires a confluence of multiply
factors (Fig. 1) [1].
Biobanks are on the list of “10 Ideas Changing the
World Right Now,” published in Time 2009 [2]. In
this article, the biobank is a safe house for tissue
samples, tumor cells, DNA and, yes, even blood—that
would be used for research into new treatments for
diseases (Fig. 2) [2].
General biobanks are much more flexible as they
can support a variety of studies, including cross-
sectional studies of genotype-phenotype correlations,
case control studies using a biobank for cases and/or
controls, and cohort studies using baseline and
follow-up data in a biobank to link genetic variation
with health outcomes [3].
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Definitions
Biobanks were defined by many authors, institutions, so-
cieties, and organizations in many different ways during
the last decade.
The big international societies like OECD, ISBER,
European Commission, and BBMRI-ERIC have expressed
their definitions.
The Organisation for Economic Co-Operation and
Development (OECD) defines a biobank as a collection
of biological material and the associated data and informa-
tion stored in an organized system, for a population or a
large subset of a population [4].
OECD in Recommendation on Human Biobanks and
Genetic Research Databases (HBGRD) [5] provides guid-
ance for the establishment, governance, management,
operation, access, use, and discontinuation of human
biobanks and genetic research databases, which are
structured resources that can be use for the purpose of
genetic research and which include:
 Human biological materials and/or information
generated from the analysis of the same;
 Extends it with associated information.
International Society for Biological and Environmental
Repositories (ISBER) defines biobank as an entity that
receives, stores, processes, and/or disseminates specimen
as needed. It encompasses the physical location as well
as the full range of activities associated with its oper-
ation [6].
Also, European Commission (EC) gave a definition.
Joint Research Centre (JRC) published in 2015 in Scien-
tific and Technical Reports a paper, Biobanking in Europe:
prospects for Harmonization and Networking, which gives
the following definition: biobanks are organized collec-
tions consisting of biological samples and associated data
of great significance for research and personalized medi-
cine [7]. Two years later, the European Commission pub-
lished another document: Report of an expert group on
Dealing with Ethical and Regulatory Challenges of Inter-
national Biobank Research: Biobanks for Europe, A chal-
lenge for governance with more comprehensive definition.
Biobanks typically:
 Collect and store biological materials that are
annotated not only with medical, but often also
epidemiological data;
 Are not static “projects,” since biological materials
and data are usually collected on a continuous or
long-term basis;
 Are associated with current and/or future research
projects at the time of specimen collection;
 Apply coding or anonymization to assure donor
privacy but have, under specific conditions,
Fig. 1 Main impacts of personalized medicine. The implementation of personalized medicine requires a confluence of multiple factors. Full
implementation of personalized medicine can only be achieved when all sectors converge toward the center. Modified from [1]
Fig. 2 Ten ideas changing the Word right now. In 2009, Time
Journal has published ten ideas that had influenced the world’s
changes. On the eighth position were biobanks as potential for
biomedical research. Modified from [2]
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provisions that participant remain re-identifiable in
order to provide clinically relevant information back
to the donor;
 Include established governance structures and
procedures (e.g., consent) that serve to protect
donors’ rights and stakeholder interests.
At the moment, the biggest player in the field of
biobanks, Pan-European Biobanking and Biomolecular
Resources Research Infrastructure (BBMRI), defines bio-
banks as follows: biobanks contain biological samples
and associated information that are essential raw mate-
rials for the advancement of biotechnology, human
health, and research and development in life science [8].
Also, many authors published various definitions of
biobanks with respect to one or some special features of
biobanks.
The very simple but generally accepted definition was
published by Kauffmann and Cambon-Thomsen in 2008
[9]: biobank is an organized collection of human bio-
logical material and associated information stored for
one or more research purposes.
And finally, the definition offered by Artene et al. [10]
clearly describes the biobank as a set consisting of two
different parts:
 The biological material that is collected, processed,
and long-time stored;
 The database, including information about
demographical and clinical data for each sample and
also associated with the bank inventory with the
main activities: biospecimen collection, processing,
storage or inventory, and distribution of biological
material.
Generally, the definition of biobank consists of three
groups of relatively distinct information:
 Biological human material;
 Attached or connected information;
 The legal issues like consent and patient/individual
data safety and protection.
It makes the science of biobank so comprehensive and
complicated because it requires a multidisciplinary and
universal approach in all stages of life cycle of the
biobank.
Time for biobanks
The idea of biobanks is not new. In many countries,
biological samples not only of human origin were col-
lected more or less systematically for many decades,
with more or less connected information of the indi-
vidual. These samples were taken randomly, collected,
stored, shared, and provided for other purposes in the
beginning without regulations and rules. At the time
the requirements for the type of the sample (blood,
urine, RNA, DNA, tissue …) size and the way how
the sample is taken, transported, saved, and preserved
became more specific and precise, it meant the quan-
titative and qualitative characteristics of samples were
specific according to the advances in biomedical and
clinical trial or research. Such great event like the se-
quencing of human genome in 2001 opened the door
to new methods on how to study diseases and disor-
ders. New and emerging technologies are based on
improved molecular profiling, better understanding of
factors, and processes leading to understanding of the
ethiopathology of diseases. These achievements en-
abled new approach to the health care based on indi-
vidual genomic, proteomic, and metabolomic profiles
[11]. The side effect of the progress in biomedical re-
search is the emergence of “big data,” large-scale data,
and information about patients’ characteristics, dis-
eases, and epidemiological, environmental, lifestyle,
and societal data which require a new approach to
handle the whole process of the sample manipulation,
and consequently biobanks.
Stratification of patients is another result and a re-
quirement for biobanks that enable a shift from
“one-size-fits-all” [11] to more targeted therapy,
therapy models, and in silico therapies. A stratified
approach based on detailed information about the
individual biological variation, complemented with
environmental, life factors, and societal information
enable to study the health and diseases in complexity
and to improve the individual health care, with re-
spect to age, sex, demography, and relevant costs
(Fig. 3) [12].
New knowledge in informatics, bioinformatics, and in-
formation technologies strongly supported and still sup-
ports the formation and development of biobanks.
Biobanking has been identified as a key area for de-
velopment in order to accelerate the discovery and
development of new drugs, recently especially in on-
cology [13].
Biobanks play an important role in identification of
new biomarkers. Population surveys and biobanking re-
search are essentials tools in the elucidation of the
etiology of complex diseases and the molecular basis of
disease subtypes. A more precise biology-based classifi-
cation of disease speeds up the development of highly
sensitive, high-throughput methods more targeted, ef-
fective, and cost-effective treatment, reduces the inci-
dence of undesired side effects of therapy, improves
access in clinical and pharmacology trial design, and
leads to new concepts of disease prevention and health
promotion [14]. Zatloukal and Hainaut [15] suggest a
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novel way of structuring biobank network according to
the clinical trial design, thus creating a step-by-step
process, starting with assessing and measuring identified
biomarkers, through to whether the biomarker is in-
formative in determining the trialed drug’s effect.
New dictionary for biobanks
As biobanking is developing to the science of biobank-
ing, new requirements are appearing regarding defini-
tions, obligations, and terminology. Scientists from
different scientific branches do not understand the terms
in the same way, and even between countries, significant
differences can be found. Fransson in his study [16]
clarifies the general understanding of several most used
terms: biobank, sample, specimen, aliquot, coding, an-
onymizing, personal data, and patient’s informed con-
sent. Some new terms have to be defined or redefined
for the purposes of biobanks like genetic data, biometric
data, and impact assessment. The study shows a consid-
erable confusion in some of the terms used in the bio-
bank community.
Modern history of biobanks
Biospecimens have been collected and stored in con-
junction with clinical and epidemiological studies for
several decades. The first biorepositories have existed in
various forms for over 150 years, from early small collec-
tions to modern automated facilities managing millions
of samples [17].
Human specimens have been collected and stored at
institutions in the USA and elsewhere for over 100 years.
Historically, these stored tissue samples have been used
by the biomedical community for educational and re-
search purposes. More recently, the stored tissues have
played a major role in understanding and treatment of
diseases [18]. The history of real biobanks is not long,
about 30 years. The first banks were repositories of ran-
domly collected samples and information; data associ-
ated with stored biospecimens have increased in the
mean time in complexity from basics, such as date of
collection and the diagnosis, to extensive information
sets encompassing many aspects of participant or patient
phenotype, now rapidly extending into genetic, prote-
omic, and other -omics information. From the histor-
ical point of view, the chronologic development was
followed by De Souza and Greenspan [19]:
 Academic/university-based repositories, possibly the
first biobanks in existence, developed almost
exclusively around single-project goals and research
requirement;
 Institutional- or government-based biobanks that
hold greater numbers of samples for a wider
research purposes;
 Commercial/for-profit biorepositories;
 Population-based biobanks, where long-term
sample acquisition from broad populations enables
longitudinal studies such as disease monitoring,
aging studies, and biomarker discovery;
 Virtual biobanks that hold no physical specimens
but offer location and retrieval services for samples
held globally or nationally.
Because the science of biobanking is very closely
linked to the development of an enabling infrastructure,
it requires scientists to work more closely with each
other and with funders than has historically been the
norm in biomedical science [20].
Types of biobanks
Before the biobanks classification from various sources will
be presented, the difference between biobank and biorepo-
sitory has to be clarified: the term biobank has been used
interchangeably with biorepository [21]. Previously OECD
used the term “biological resource center” not only for re-
positories, but also for suppliers of health research services
[5]. The International Agency for Research on Cancer
(IARC) used the term “biological resource center” for
Fig. 3 Personalized medicine contribution to better health care. Stratification of patients is another result and requirement for the biobanks that
enable shift from “one-size-fits-all” 11 to more targeted therapy, therapy models, and in silico therapies. A stratified approach enables to improve
the individual health care, with respect to age, sex, demography, and relevant costs. Modified from [12]
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collections of human cancer samples [22]. In the USA, the
National Cancer Institute defined the term biorepository as
an organization, place, room, or container where biospeci-
mens are stored…in a freezer by an individual researcher
[23]. Likewise, the term biobank has been used in this con-
text by other US and European institutions [22].
Classification of biobanks is not simple and is based
on different approaches: there are various types of
biobanks like population-based, diseases-oriented, hos-
pital- or academic- based, networked, or run by the
government, non-profit organizations, or commercial
companies among others [24].
Biobanks also vary in scale, nature, contents, and par-
ticipants. Some definitions overlap, and in definition of
biobanks, they may be “radically contrasting views over
how certain attributes should be identified, formulated,
defined, or ranked…” [25].
Human biobank classification (according to biomedin-
vo4all website) [26] is based on:
 Tissue type (tumor tissue, cells, blood, DNA, or
DNA array results);
 Purpose/intended use (research, forensics,
transplantation, source for therapeutics, e.g.,
umbilical blood, stem cell biobanks for individual or
community use, or diagnostics);
 Ownership (academic and research institutions,
hospitals, biotechnology and pharmaceutical
companies, and stand-alone biobank companies
and foundations may hold biobanks.
Ownership may be private, public, or in partnership
across sector boundaries (ownership may be public,
managed in partnership with government).
 Volunteer group/group of participants (population-
based, such as all newborns, adults, or pregnant
women, or disease-based, including only those with
a specific disease).
 Size (disease group, regional, statewide, or national).
Gottweis and Zatloukal [27] defined four basic types
of research biobanks:
 Clinical/control based on biological specimen from
patients with specific diseases and from non-
diseased control;
 Longitudinal population-based biobanks that follow a
portion of the population over a large period of time;
 Population isolate biobanks with a homogenous
genetic and environmental setup of the population
represented;
 Twin registries with samples from monozygotic and
dizygotic twins.
Rebulla et al. [28] classification is even broader and
identifies six types of biobanks:








Currently, the generally accepted classification comes
from the pan-European Biobanking and Biomolecular
Resources Research Infrastructure (BBMRI) [8], which
distinguishes between only two types of biobanks:
 Population-based biobanks (population-based
prospective biobanks focused on the study of the
development of common, complex diseases over
time).
 Disease-oriented biobanks (biobanks of tissue
samples and clinical data also referred to as disease
oriented or clinical biobanks).
What kind of human material is collected in biobanks?
The world’s most comprehensive directory of biobanks,
tissue banks, and biorepositories collect blood, whole
blood, plasma, serum, RBC, white cells, ducal swab,
DNA, RNA, protein, cell lines, fluid, urine cerebrospinal
fluid, synovial fluid, amniotic fluid buffy coat, bone mar-
row stem cells, and tissue provided by Global Bank Dir-
ectory, Tissue Banks, and Biorepositories [29].
Infrastructures and international projects of biobanks
Biobanks encompass a unique research infrastructure
that requires different governance mechanisms than
project-based research. The governance mechanisms
must balance the needs of the scientific community
and the participants with an emphasis on the recogni-
tion of participants, trustworthiness, and adaptive
management [30].
In recent years, biobanks across the globe have re-
ceived much attention as a new key infrastructure and
resource for biomedical research and drug development.
Increasingly, biobanks are becoming networked and
even international projects in the context of post-
genomic medical research [31].
Biobank consortium EuroBioBank (EBB) network
(www.eurobiobank.org) was the first operating network
of biobanks in Europe to provide human DNA, cell, and
tissue samples for research on rare diseases (RDs). The
EBB was established in 2001 to facilitate access to rare
disease biospecimens and associated data; it obtained
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funding from the European Commission in 2002 as a
project in the 5th Framework Programme (FP5) and
started operation in 2003 [32].
The most important and the biggest infrastructure in
Europe and even all over the world is Biobanking and
BioMolecular resources Research Infrastructure—Euro-
pean Research Infrastructure Consortium (BBMRI-ERIC,
http://www.bbmri-eric.eu/). BBMRI:
 Pan-European distributed infrastructure of existing
and new bio-banks and biomolecular resource
centers;
 Provides access to human biological samples that are
considered as essential raw material for the
advancement of biotechnology, human health, and
research and development in Life Sciences (e.g.,
blood, tissues, cells or DNA that are associated with
clinical and research data);
 Comprises biomolecular research tools and bio-
computational tools to optimally exploit this
resource for global biomedical research.
The mission of BBMRI-ERIC is to increase efficacy and
excellence of European biomedical research by facilitation
access to quality-defined human health/disease-relevant
biological resourced through:
 The inclusion of associated data in an efficient and
ethically and legally compliant manner;
 By reducing the fragmentation of the biomedical
research landscape through harmonization of
procedures, implementation of common standards,
and fostering high-level collaboration;
 By capacity-building in countries with less developed
biobanking communities thereby contributing to
Europe’s cohesion policy and strengthening the
ERA.
The science of biobanks
The science of biobanks is very broad and diverse and
includes research, education, funding, publishing, bio-
banking services, and others. A lot of activities have ap-
peared to support the development of biobanks. In 2005,
Office of Biobanking and Biospecimen Research (OBBR)
was based in the frame of US National Cancer Institute
(NCI). Also, in Europe, a lot of activities supporting the
biobank development have been raised, some of them in
the frame of 7th Framework Programme of EU (FP7)
in years 2007–2013 and continues in the following
framework program, Horizon 2020 (2014–2020). EU
funded projects are pioneering the development of
techniques for population genetics and performing
large population studies on the genetic predisposition
to major diseases. Support is also provided for
development of harmonization protocols and for col-
lection, storage, and management of patient samples
and of genetic data across Europe. Recognizing the
power of population-based approaches to study genetic
susceptibility for disease, between 2002 and 2008, the
European Commission’s Framework Programmes for Re-
search and Technology Development (RTD) have pro-
vided more than €60 million to collaborative research
projects in this area. The most relevant projects are men-
tioned here.
Project P3G (the Public Population Project) in Gen-
omics is an international consortium with members in
40 countries. It aims to lead, catalyze, and coordinate
international efforts and expertise, so as to optimize the
use of studies, biobanks, research databases, and other
similar health and social research infrastructures (http://
www.p3g.org).
Project SPIDIA (Standardisation and improvement of
genetic Pre-analytic tools and procedures for In-vitro
DIAgnostics, http://www.spidia.eu) was launched in
2009 and brought together 16 academic institutions,
international organizations, and life sciences companies.
The project aid is to standardize and improve pre-
analytical procedures for in vitro diagnostic testing [13].
The ENGAGE (http://www.euengage.org/) consortium
has brought together 24 leading research organizations
and two biotechnology and pharmaceutical companies
across Europe and in Canada and Australia. ENGAGE
aims to translate the wealth of data emerging from large-
scale research in genetic and genomic epidemiology from
European (and other) population cohorts into information
relevant to future clinical applications. The concept of
ENGAGE is to enable European researchers to identify
large numbers of novel susceptibility genes that influence
metabolic, behavioral, and cardiovascular traits and to
study the interactions between genes and lifestyle bio-
markers factors.
The ENGAGE consortium will integrate and analyze
one of the largest ever human genetics dataset (more
than 80,000 genome-wide association scans and DNAs
and serum/plasma samples from over 600,000 individ-
uals). One goal is to demonstrate that the findings from
ENGAGE can be used as new diagnostic indicators for
common diseases that will help us to understand better
risk factors, disease progression, and why people differ
in responses to treatment.
HYPERGENES project (http://www.hypergenes.eu)
is focused on the definition of a comprehensive genetic
epidemiological model of complex traits like essential
hypertension (EH) and intermediate phenotypes of hyper-
tension dependent/associated target organ damages (TOD)
as well as other endophenotypes as the pharmacogenomic
pattern of drugs widely used in EH. The discovery of the
genetic component in common complex diseases is
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extremely challenging since most of them are multifac-
torial and since the genetic component is likely to be
described by the interactions of several genes involved
in the disease pathway, each predisposing imperceptibly
to the disease. HYPERGENES adopted the genome-
wide association (GWA) approach to identify common
variants contributing to the inherited component of
common diseases.
The GEN2PHEN project (http://www.gen2phen.org/)
aims to unify human and model organism genetic vari-
ation databases toward increasingly holistic views into
genotype-to-phenotype (G2P) data, and to link this sys-
tem into other biomedical knowledge sources via gen-
ome browser functionality. The project will establish the
technological building-blocks needed for the evolution
of today’s diverse G2P databases into a future seamless
G2P biomedical knowledge environment, by the pro-
ject’s end. This will consist of a European-centered
but globally networked hierarchy of bioinformatics
GRID-linked databases, tools and standards, all tied
into the Ensemble genome browser.
All together, 34 projects were/are supported by Euro-
pean Commission in FP7, and the process continues in
Horizon 2020.
Not only framework programs of European Union
support the biobanking in Europe and all over the
world, but also other international initiatives contrib-
ute to the development of biobanking. Innovative
Medicines Initiative (IMI, http://www.imi.europa.eu/),
Europe’s largest public-private initiative, is aiming to speed
up the development of better and safer medicines for
patients. IMI supports collaborative research projects and
builds networks of industrial and academic experts in
order to boost pharmaceutical innovation in Europe. IMI is
a joint undertaking between the European Union and the
pharmaceutical industry association—European Federation
of Pharmaceutical Industries and Associations (EFPIA)
(Fig. 4) [33].
Internalization
A multitude of national and regional population-based
and disease-oriented biobanks have been established in
Europe. However, the exchange of data and materials
within national legal frameworks is still difficult and
European biobanking efforts are characterized by frag-
mentation [34]. Despite the unique European strength,
value and irreplaceable national collections suffer from
underutilization due to fragmentation of the European
biobanking research community. Promising inter-
national initiatives are challenged by the heterogeneous
legal, ethical, and societal environments. There is an ur-
gent need for coordination and harmonization of the
biobanking.
Many of the scientific institutions, which are currently
in the process of establishing or using biobanks may be
operating in a legal “gray zone,” because:
 There are currently very few specific legal
regulations pertaining to such collections;
 Where such regulations do exist, they vary greatly
between different countries;
 Solid experience of legal practice is widely lacking in
the field of biobanking.
Furthermore, a comprehensive assessment of the legal
standing of a biobank would severely strain the logistical
and financial resources of most interested institutions [35].
Biobanks are embedded in complex networks of re-
search collaborations that span regions and countries. At
the moment, no single laboratory, institution, or country
is able to cover the whole problematics of biobanking.
International multidisciplinary cooperation is the corner-
stone in the complex process of biobank development
and operational functioning.
Biobanks, bioinformatics, and ICT
The ability to correlate data and biospecimens from dif-
ferent biobanks is crucial to accelerating the pace of
translational research. A meta-model to describe infor-
mation about a biobank is already under construction as
a first-step data sharing among biobanks that exhibit
tremendous heterogeneities. This work is being con-
ducted internationally to help harmonize the national
biobanks participating in the Biobanking and Biomolecular
Resources Research Infrastructures Initiative (BBMRI)
(http://www.bbmri.eu/index.php/). Information about
the participating biobanks is captured by a common
set of attributes (minimum data set) designed to
adopt different kinds of collections. The latest inter-
operability and semantic web technologies can be
used for building resource description frameworks for
data and services providing flexible frameworks that
can be used in different data-sharing scenarios.
Ethical, legal, and social issues (ELSI)
Ethical issues are commonly present in many aspects of
biobanking. The fact that biobanks deal with human
samples, invading an individual autonomy or limiting
self-control, provokes a number of ethical issues [36].
The use of biobanks is increasing and raises a lot of
ethical, legal, and social issues. In addition to these, there
are also other issues which have to be taken in account
such as equipment which means processing, annotation,
storage, and operating procedures like samples accrual,
processing, annotation, storage, release, distribution, and
tracking. Any kind of related information must be con-
sidered: clinical informatics like pathology, treatment,
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outcome data, and database structures and as mentioned
above, patient (informed) consent, preference list, inven-
tory management tools, and query tools. And finally,
national policies, economic models including funding
sources, user fees, intellectual property, governance
models, and education and training of all stakeholders
(the donors, investigators, funding agencies, institution
housing the biosamples and ethics review committee)
have to be included.
Currently, most actual questions that have to be an-
swered are as follows. What are the ethical trends and
legal frameworks in the post-genomic era? Are there
new issues in relation to the developments of techniques
and new study designs? How does this affect the clini-
cian’s attitudes and relationship with the patients? The
main ethical issues encountered are informed consent,
confidentiality, secondary use of samples and data over
time, and return of results [37, 38].
Fig. 4 The projects including biobanking activities supported by Innovative Medicines Initiative 2 (2009–2014). Modified from [32]
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Informed consent
Informed consent [39] according to international con-
ventions and guidelines principles in research ethics is
to guarantee the voluntary participation in research
and address privacy issues in research. Informed con-
sent consists of three basic components: adequate in-
formation, voluntariness, and competence. It means
that prior to consenting, a participant should be in-
formed of the goal of his participation and research,
possible risks and adverse event, and the possibility to
refuse or withdraw from research at any time. Informed
consent is required when the research involves the par-
ticipation of human beings, when the research uses
genetic material or biological samples, and when the
research involves personal data. Informed consent
should respect individuals’ autonomy and vulnerability.
Special attention must be paid to specific groups of
participants like children, elderly, mentally deficient
persons, severely injured patients, and participants with
specific cultural or traditional background, ethnic
specificity, and so on.
Recently, the discussion has focused on the problem
if the consent has to be general or broad [37]. The
more general consent is less informed; on the other
hand, it averts all aspects relevant to the patient’s
choice. The existence of different terms has posed a
major problem for discussions on confidentiality is-
sues. European Medicines Authority (EMEA) has pro-
posed the terminology and nomenclature that has
been adopted by the International Conference on
Harmonization of Technical Requirements [40]. The
nomenclature is in basic terms as follows: identified
data and samples are labeled with personal identifiers
such as name or identification numbers; coded data
and samples are labeled with at least one specific
code and do not carry any personal identifiers; and
anonymized data and samples are initially single or
double coded, but the link between the subjects’ iden-
tifiers and the unique code(s) is subsequently deleted.
Once the link has been deleted, it is no longer pos-
sible to trace the data and samples back to individual
subjects through the coding key(s). The discussion
about absolute safety has led to the new term open
consent model proposed by Lunshof et al. [41], which re-
frains from any promises of anonymity, privacy, or confi-
dentiality [31].
Confidentiality, privacy, and data protection
Data protection and privacy are fundamental human
rights which need to be protected at all time [42].
Participants want to have control over their personal
information and personal communications, and these
should be treated confidentially. Data protection
guarantees the right to privacy. Data protection reveres
to the technical framework and security measures
designed to guarantee that all personal data are safe
from unforeseen, unintended, or malevolent use. Data
protection therefore includes both measure with regards
to access to data and the conservation of data. Also,
accuracy of data can be included in a data protection
strategy.
A very important issue is (personal) data owner-
ship. Since there are clearly multiple stakeholders in
a biobank—the donors, investigators, funding agen-
cies, institution housing the biosamples, and ethics
review committee—it has been proposed that the in-
stitution of the biobank should hold “custodianship”
for the use of the resource, and that the custodian of
the samples should fulfill numerous responsibilities
[43].
Sharing the best practices and procedures in biobanks
requires the process of harmonization. Harmonization is
a more flexible approach aimed at ensuring the effective
interchange of valid information and samples [44]. The
importance of the harmonization process is to articulate
those situations in which true standardization is required.
Standardization means precisely the same protocols/
standard operating procedures (SOPs) used by all bio-
banks. Likewise, comparison of high-throughput-
technology-derived data requires that platforms and
operational details be identical. Harmonization is
context-specific and pertains to the compatibility of
methodologies and approaches to facilitate synergistic
work. It thereby relates to the critical areas of gener-
ating, sharing, pooling, and analyzing data and bio-
logical samples to allow combining resources and
comparing results obtained from different biobanks.
Harmonization includes technologies and procedures
for phenotype characterization, sample handling, in vitro
assays, computational biology analytical tools and algo-
rithms, data-coding, and electronic-communication proto-
cols that enable biobanks to network together within
compatible ethic-legal frameworks [20].
Harmonization initiatives have brought together indi-
viduals with diverse expertise. On the basis of consensus,
they have developed standards, tools, technologies, and
resources, which are widely available to the biobanking
community today [45]. Currently, the biobanks differ in
structure, purpose, and design. That is why they contrib-
ute to the generation and translation of knowledge to
clinics, public health, and technology in different ways,
and the process of harmonization of the practices,
polices, and operations is heavy going. Despite this,
harmonization fosters the amount of data and specimens
useable, and translational science will rely on fundamen-
tal biological data to (re)classify human disease on the
basis of causality and to identify relevant drug targets
and biomarkers [46].
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Biobanks and personalized medicine
Personalized medicine is currently characterized as “4P,”
personalized, preventive, predictive, and participatory [47].
Biobanks can contribute to all of these characteristics:
 Personalization reflects the achievements in genetic
science in individualized digital genome.
 Predictiveness reflects the ability to predict the risk
of certain disease based on information of individual
genome in combination with additional information
like age, sex, lifestyle, and social and environmental
data.
 Preventiveness reflects the individual ability to avoid
or minimize risk factors for certain disease.
 Participation reflects the individual proactive
behavior in the whole process of health care; it
means empowerment of individuals to undertake
informed decisions about their health future.
The European Association for Predictive, Preventive &
Personalised Medicine (EPMA) as a key player in the
field of personalized medicine in Europe consider
biobanking as an integral part of personalized medicine
approach to the health care and strongly supports the
future biobank development [48–50].
Future of biobanks
Despite the progress, biobanks still face a lot of issues to
be solved in the whole process of biobanking (Fig. 5)
[51]. Biobanking is facing the lack of harmonization, lack
of standards, agreed vocabulary, common data elements,
and best practices for collecting data and processing
samples. An accreditation and evaluation system to
recognize biobanks that provide high-quality samples,
and reward and acknowledge scientists, who establish
and maintain biobanks, should be established [32].
However, most European citizens have never heard of
biobanks, nor do they know of their importance in re-
search. Education at any level is the underestimated
issue. The current discussion is on people’s and/or
patients’ engagement with biobanks and people’s
willingness to participate in biobanks.
Furthermore, the legal and regulatory frameworks that
apply to this area are fragmented little interest in fund-
ing small biobanks that contain and exchange limited
numbers of samples.
Long-term sustainability is a major challenge for bio-
banking. A number of considerations are critical to
keeping biobanks and the research they support active
and dynamic. The need for long-term investments into
biological resources is clearly evident when longitudinal
data are needed. Prospective collections of data and
samples from asymptomatic individuals will allow future
identification of premorbid and subclinical periods of
disease development and will identify prognostic and
diagnostic biomarkers and drug targets [52].
Conclusions
Biobanks are complex systems of systematically pro-
grammed storage of human material and associated data.
In the past 20 years the science of biobanks has became
an integral part of personalized medicine and a great
number of biobanks have been established all over the
world to support the dramatic development in diseases
prevention, prediction, diagnosis and treatment.
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